Table 1.
Analysis of distribution of bevacizumab in the aqueous, vitreous, and serum after intravitreal injection of 1.25 mg/0.05 mL bevacizumab in the right eye
| Compartment | t1/2 (days) | Tmax (days) | Cmax (ng/mL) | % of vitreous Cmax | AUC0→∞ (μg/mL * day) | Exposure to bevacizumab as a % of vitreous exposure |
|---|---|---|---|---|---|---|
| Vitreous (R) | 6.61 | 1 | 406250 | – | 1455.1 | – |
| Aqueous (R) | 6.51 | 1 | 5835 | 1.44 | 44.8 | 3.08 |
| Serum | 5.87 | 8 | 413 | 0.10 | 5.3 | 0.36 |
| Aqueous (L) | 5.56 | 8 | 1.61 | 0.0004 | 0.018 | 0.001 |
| Vitreous (L) | – | 8 | 0.34 | 0.00008 | 0.017 | 0.001 |
Abbreviations: R, right eye; L, left eye; Tmax, day when concentration of bevacizumab peaked; Cmax, maximum concentration; AUC, area under the curve.